Literature DB >> 24531907

Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.

R Gagliardini1, M Fabbiani, S Fortuna, E Visconti, P Navarra, R Cauda, M Colafigli, A De Luca, E M Trecarichi, S Di Giambenedetto.   

Abstract

Etravirine is metabolized by three cytochrome P450 enzymes that are in turn induced by rifampin. Consequently, co-administration of etravirine and rifampin is not recommended. To date, however, no clinical studies exploring the drug-drug interaction of this combination have been conducted. Here we report two cases of off-label etravirine use concurrently with antitubercular treatment, dictated by the unavailability of other treatments. Plasma drug concentrations were monitored by regular measurements. Our results appear to confirm the increased metabolism of etravirine through the induction of cytochrome P450 enzymes, but the adequacy of drug levels in all of the measurements and subsequent virological suppression suggest that this drug interaction may not be clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24531907     DOI: 10.1007/s15010-014-0599-z

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  6 in total

1.  Etravirine concentrations in CSF in HIV-infected patients.

Authors:  J M Tiraboschi; J Niubo; A Vila; S Perez-Pujol; D Podzamczer
Journal:  J Antimicrob Chemother       Date:  2012-02-22       Impact factor: 5.790

Review 2.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

3.  Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.

Authors:  Massimiliano Fabbiani; Simona Di Giambenedetto; Laura Bracciale; Alessandra Bacarelli; Enzo Ragazzoni; Roberto Cauda; Pierluigi Navarra; Andrea De Luca
Journal:  J Antimicrob Chemother       Date:  2009-04-27       Impact factor: 5.790

4.  Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers.

Authors:  T N Kakuda; M Schöller-Gyüre; G De Smedt; G Beets; F Aharchi; M P Peeters; K Vandermeulen; B J Woodfall; R M W Hoetelmans
Journal:  HIV Med       Date:  2009-01-07       Impact factor: 3.180

5.  Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.

Authors:  Thomas N Kakuda; Monika Schöller-Gyüre; Cassy Workman; Keikawus Arasteh; Anton L Pozniak; Goedele De Smedt; Greet Beets; Monika Peeters; Kati Vandermeulen; Brian J Woodfall; Richard M W Hoetelmans
Journal:  Antivir Ther       Date:  2008

6.  Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.

Authors:  Thomas Kakuda; Vanitha Sekar; Peter Vis; Bruce Coate; Robert Ryan; David Anderson; Guy De La Rosa; Joseph Mrus
Journal:  AIDS Res Treat       Date:  2012-03-21
  6 in total
  4 in total

1.  Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine.

Authors:  Devinder Sharma; Aik Jiang Lau; Matthew A Sherman; Thomas K H Chang
Journal:  Br J Pharmacol       Date:  2015-02-10       Impact factor: 8.739

2.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

Review 3.  Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected children.

Authors:  Helena Rabie; Lisa Frigati; Anneke C Hesseling; Anthony J Garcia-Prats
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

4.  Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.

Authors:  Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.